Business
NurExone Biologic Inc. to Begin Trading on TSX Venture Exchange and Retains Market Maker
Bnei-Brak, Israel--(Newsfile Corp. - June 22, 2022) - NurExone Biologic Inc. (formerly, Ener...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Biologic Inc. to Begin Trading on TSX Venture Exchange and Retains Market MakerBnei-Brak, Israel--(Newsfile Corp. - June 22, 2022) - NurExone Biologic Inc. (formerly, EnerSpar Corp.) (TSXV: NRX) (\"NurExone\" or the \"Company\") is pleased to announce that, further to its press release of June 15, 2022 announcing the closing of its reverse takeover transaction, it will commence trading on the TSX Venture Exchange (the \"TSXV\") under its new symbol \"NRX\" effective at the market opening today. NurExone also announces that it has engaged Questrade, Inc. (\"Questrade\") to provide market making services for a fee of $5,500 per month. The engagement is for an initial term of one year, and is automatically renewable for successive one year terms unless terminated by either party providing written notice at least 30 days prior to the end of the term. NurExone and Questrade are unrelated entities. Questrade will be compensated on a fee for service basis only, and will not receive shares or options as compensation from NurExone for its services. NurExone is a pharmaceutical company developing a biological extracellular vesicles (EV)-based technology drug platform. This is a unique advanced treatment for reversing paralysis and improving the quality of life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified siRNA sequence. This technology, which has been successfully used in animal studies, after it is approved in clinical trials, can be used to treat various conditions such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. NurExone holds an exclusive worldwide license to develop and commercialize the technology by the Technion - Israel Institute of Technology, Haifa and Tel Aviv University, both located in Israel. As well, the Company has recently obtained an additional exclusive global license to an exosome manufacturing process developed at the Technion - Israel Institute of Technology, Haifa. NurExone will be responsible for ongoing exosome research, management of clinical studies and commercialization of the technology for different indications not limited to the central nervous system.ON BEHALF OF THE BOARD OF DIRECTORS:Dr. Lior Shaltiel, Chief Executive Officer and Director.Email: [email protected] Pho...